Zimmer Partners’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Zimmer Partners’s Portfolio AYLA Stock Details AYLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-125,000	Closed	-$1.26M	–	169
2020 Q2	$1.26M	Buy	+125,000	New	+$1.74M	0.02%	95

Other funds holding AYLA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Zimmer Partners's AYLA Position: Q3 2020 in Review

Zimmer Partners sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q3 2020, closing a stake of 125,000 shares — an estimated $1.26M sold.

Zimmer Partners first reported a position in AYLA in Q2 2020 and held it in 1 quarter. The position peaked at $1.26M in Q2 2020. 7 funds tracked by Wall St. Rank hold AYLA as of Q3 2020.

Zimmer Partners reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Zimmer Partners sold 125,000 Ayala Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $1.26M.
Zimmer Partners first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
Zimmer Partners's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $1.26M in Q2 2020.
7 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Zimmer Partners's 13F filing for Q3 2020, filed 16 Nov 2020.